- Home
- TSAT vs LXEO Comparison
TSAT vs LXEO Comparison
Compare TSAT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- LXEO
- Stock Information
- Founded
- TSAT 1969
- LXEO 2017
- Country
- TSAT Canada
- LXEO United States
- Employees
- TSAT N/A
- LXEO N/A
- Industry
- TSAT Metal Fabrications
- LXEO
- Sector
- TSAT Industrials
- LXEO
- Exchange
- TSAT Nasdaq
- LXEO Nasdaq
- Market Cap
- TSAT 236.1M
- LXEO 252.4M
- IPO Year
- TSAT 1996
- LXEO 2023
- Fundamental
- Price
- TSAT $17.18
- LXEO $6.14
- Analyst Decision
- TSAT Hold
- LXEO Strong Buy
- Analyst Count
- TSAT 1
- LXEO 5
- Target Price
- TSAT $9.00
- LXEO $23.80
- AVG Volume (30 Days)
- TSAT 84.9K
- LXEO 274.8K
- Earning Date
- TSAT 11-14-2024
- LXEO 12-31-2024
- Dividend Yield
- TSAT N/A
- LXEO N/A
- EPS Growth
- TSAT N/A
- LXEO N/A
- EPS
- TSAT 2.55
- LXEO N/A
- Revenue
- TSAT $450,756,875.00
- LXEO N/A
- Revenue This Year
- TSAT N/A
- LXEO N/A
- Revenue Next Year
- TSAT N/A
- LXEO N/A
- P/E Ratio
- TSAT $6.61
- LXEO N/A
- Revenue Growth
- TSAT N/A
- LXEO N/A
- 52 Week Low
- TSAT $6.93
- LXEO $5.77
- 52 Week High
- TSAT $18.80
- LXEO $22.33
- Technical
- Relative Strength Index (RSI)
- TSAT 60.44
- LXEO 35.77
- Support Level
- TSAT $16.13
- LXEO $6.78
- Resistance Level
- TSAT $18.80
- LXEO $7.40
- Average True Range (ATR)
- TSAT 1.40
- LXEO 0.66
- MACD
- TSAT 0.12
- LXEO -0.13
- Stochastic Oscillator
- TSAT 63.58
- LXEO 1.34
About TSAT Telesat Corporation and Class B Variable Voting Shares
Telesat Corp is a global satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.